EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in Greece
← catalyst calendarNCT06724575 · readout in 681 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
155actual
Sites
8
Country
Greece
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-17 | actual | When the study began enrolling |
| Primary completion | 2028-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Primary outcome
what the primary-completion date above is the date OFChange in the ACQ-6 score at baseline and up to 104 weeks post-index
measured Before treatment initiation and at Weeks 4, 12, 24, 52, 72, 104 after treatment initiation
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed